Livzon Pharma (01513) announced its mid-term performance in 2024, with revenue of approximately 6.282 billion yuan, a decrease of 6% year-on-year...
Zhixin Finance App News, Livzon Pharma (01513) announced its mid-term performance in 2024, with revenue of approximately 6.282 billion yuan, a decrease of 6.09%; the net income attributable to the company's shareholders is approximately 1.171 billion yuan, an increase of 3.21% year-on-year; The net income attributable to the company's shareholders after deducting non-recurring gains and losses is approximately 1.155 billion yuan, an increase of 5.65% year-on-year. The basic earnings per share is 1.27 yuan.
In the first half of 2024, in the environment of stricter domestic industry regulation and access policies, the group has always adhered to the mission of "patient life quality first" and the vision of "becoming a leader in the pharmaceutical industry", focusing on the steady operation and development layout of the core innovative pharmaceutical business. In terms of operations and management, the company continuously leverages the advantages of its diversified business structure and operational management, actively addresses industry and market challenges, further enhances operational management and research and development efficiency, and intensifies digital transformation efforts. It continues to strengthen product competitive advantages in terms of clinical evidence, quality, cost, market share, and other aspects, further consolidating the foundation and capabilities for sustainable corporate development.